ArticleACS omega2025
Identification of Protein-Protein Interaction (PPI) Sites on the Influenza A (H1N1) Viral Genome Using Gradient Boosting and Artificial Neural Network (ANN) Models.
Article in ACS omega, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Identification of protein-protein interaction (PPI) sites is crucial for understanding molecular recognition. Experimental identification of PPI is expensive, time-consuming, and laborious. A large number of computational methods addressed this problem. However, no computations specifically addressed PPI site prediction for the frequently mutating influenza A virus (IAV) genome that invades human hosts. For the first time, we report the prediction of PPI sites on the IAV genome (protein sequences). The method was benchmarked across various machine-learning models, optimizing class imbalance and unlabeled data types. The best-performing models were (i) the gradient boosting model, augmented with minority class oversampling and positive unlabeled (PU) learning and (ii) the protein-specific bidirectional encoder representations from transformers (Prot-BERT) combined with an artificial neural network (ANN) (termed the Prot-BERT-ANN model), adjusted with class weight correction and threshold tuning. The models were trained on two types of interaction site data sets: one obtained from diverse protein families (Train-1) (17995 amino acid sites) with known interaction sites from protein structures and the other from the IAV consensus protein sequences (3322 amino acid sites) with experimentally annotated PPI sites on the conserved regions of the proteins (Train-2). External validation was performed on two test data sets: (i) from six IAV proteins, M1, NS1, NEP, NP, PB1, and PB2, reported to interact with host factors, with experimentally annotated PPI sites on the nonconserved region of the proteins (Test-1), and (ii) the SARS-CoV-2 spike protein sequence (195 amino acid sites) (Test-2). Blind prediction was performed on three IAV protein sequencesNA, HA, and M2curated from the Human Viral Interaction Database (HVIDB). The prediction aimed to decipher the effect of amino acid substitutions on the protein-protein interaction sites of the viral genome. The gradient boosting method with oversampling and PU learning, trained on the Train-2 data set, consistently performed better on both external validation data sets. The recall values obtained from the predictions on the Test-1 data set were compared with the published D-SCRIPT (a neural language-based model) results. The gradient boosting model showed a higher average recall value (0.53 ± 0.04) for six IAV proteins compared to the D-SCRIPT results (0.18 ± 0.19). The gradient boosting prediction for the experimentally reported PPI sites on the SARS-CoV-2 spike protein (Test-2 data set) was 55% accurate, despite Test-2 being independent of Train-2. The results indicated the generalizability and interpretability of the gradient boosting model for IAV PPI site predictions. The effects of amino acid substitutions on PPI sites were demonstrated on five Matrix 1 (M1) protein sequences. This approach could be used to identify the PPI sites on newly emerging viral strains (e.g., influenza virus, SARS-CoV-2, etc.) with potential applications for drug design, improvement of drug binding, or drug repurposing, subject to further validation.
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.